ATHX Key Stats
- ATHERSYS, INC / NEW Financials May 21
- Wider-Than-Expected Loss at Athersys May 15
- Wider-Than-Expected Loss at Athersys - Analyst Blog Zacks May 15
- Athersys Management Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 14
- On The Fly: After Hours Movers May 14
- Athersys, Inc. (ATHX) Misses Q1 Views Street Insider May 14
- Athersys Reports First Quarter 2013 Results GlobeNewswire May 14
- Elan in Royalty Deal with THRX May 14
- Celgene Attains 52-Week High May 14
- Elan in Royalty Deal with THRX - Analyst Blog Zacks May 14
ATHX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Athersys is up 22.54% over the last year vs S&P 500 Total Return up 27.77%, Osiris Therapeutics up 72.19%, and Cleveland BioLabs up 37.19%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ATHX
Pro Report PDF for ATHX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ATHX Pro Report PDF
Pro Strategies Featuring ATHX
Did Athersys make it into our Pro Portfolio Strategies?